- Home
- QVCGA vs BOLD Comparison
QVCGA vs BOLD Comparison
Compare QVCGA & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QVCGA
- BOLD
- Stock Information
- Founded
- QVCGA 1991
- BOLD 2018
- Country
- QVCGA United States
- BOLD United States
- Employees
- QVCGA N/A
- BOLD N/A
- Industry
- QVCGA
- BOLD
- Sector
- QVCGA
- BOLD
- Exchange
- QVCGA NYSE
- BOLD Nasdaq
- Market Cap
- QVCGA 25.6M
- BOLD 24.4M
- IPO Year
- QVCGA N/A
- BOLD 2024
- Fundamental
- Price
- QVCGA $3.94
- BOLD $1.19
- Analyst Decision
- QVCGA
- BOLD Buy
- Analyst Count
- QVCGA 0
- BOLD 3
- Target Price
- QVCGA N/A
- BOLD $4.00
- AVG Volume (30 Days)
- QVCGA 657.9K
- BOLD 105.1K
- Earning Date
- QVCGA 08-07-2025
- BOLD 08-11-2025
- Dividend Yield
- QVCGA N/A
- BOLD N/A
- EPS Growth
- QVCGA N/A
- BOLD N/A
- EPS
- QVCGA N/A
- BOLD N/A
- Revenue
- QVCGA $9,800,000,000.00
- BOLD N/A
- Revenue This Year
- QVCGA $2.89
- BOLD N/A
- Revenue Next Year
- QVCGA $0.45
- BOLD N/A
- P/E Ratio
- QVCGA N/A
- BOLD N/A
- Revenue Growth
- QVCGA N/A
- BOLD N/A
- 52 Week Low
- QVCGA $2.27
- BOLD $1.00
- 52 Week High
- QVCGA $37.27
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- QVCGA N/A
- BOLD N/A
- Support Level
- QVCGA N/A
- BOLD N/A
- Resistance Level
- QVCGA N/A
- BOLD N/A
- Average True Range (ATR)
- QVCGA 0.00
- BOLD 0.00
- MACD
- QVCGA 0.00
- BOLD 0.00
- Stochastic Oscillator
- QVCGA 0.00
- BOLD 0.00
About QVCGA QVC GROUP INC
QVC Group Inc is a live social shopping company with six retail brands QVC, HSN, Ballard Designs, Frontgate, Garnet Hill, Grandin Road, and other minority interests. QVC offers assortment of ,quality merchandise and classifies its products into six groups: home, apparel, beauty, accessories, electronics and jewelry. The company has three reportable segments: QxH, QVC International, and CBI. Majority of revenue is from Home products, from QxH segment. Company also operates in Japan, Germany and Other foreign countries.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.